XML 20 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenues
 3 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
REVENUES
REVENUES
Product Revenues
The Company’s net revenues consisted of the following for the three months ended March 31, 2017 and 2016:
 
Three months ended March 31,
 
2017
 
2016
Products:
 
 
 
Acetadote
$
1,265,440

 
$
1,837,462

Omeclamox-Pak
645,325

 
760,319

Kristalose
2,386,591

 
3,617,806

Vaprisol
684,548

 
368,047

Caldolor
813,027

 
1,071,968

Ethyol
3,666,808

 
—

Other
175,016

 
81,930

Total net revenues
$
9,636,755

 
$
7,737,532


Cumberland supplies Perrigo Company ("Perrigo") with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $0.9 million and $1.2 million for the first quarter of 2017 and 2016, respectively.
Other Revenues
The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.